Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
4 hedge funds and large institutions have $29K invested in Northwest Biotherapeutics, Inc. Common stock in 2017 Q1 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 0 reducing their positions, and 6 closing their positions.
50% less funds holding
Funds holding: 8 → 4 (-4)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
100% less capital invested
Capital invested by funds: $8.84M → $29K (-$8.81M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WPP
Whalerock Point Partners
Providence,
Rhode Island
|
+$5K |
| 2 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WIM
Woodford Investment Management
London,
United Kingdom
|
-$8.64M |
| 2 |
CDH
Charles D. Hyman
|
-$87K |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
-$44K |
| 4 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$23K |
| 5 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$11K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MBT
1
Montecito Bank & Trust
Santa Barbara,
California
| $19K | – | – | – |
|
|
WPP
2
Whalerock Point Partners
Providence,
Rhode Island
| $5K | +$5K | +20,000 | New |
|
|
MPI
3
Mairs & Power Inc
St Paul,
Minnesota
| $3K | – | – | – |
|
|
GT
4
Glenmede Trust
Philadelphia,
Pennsylvania
| $2K | +$2K | +12,150 | New |
|
|
WIM
5
Woodford Investment Management
London,
United Kingdom
| – | -$8.64M | -24,815,028 | Closed |
|
|
CDH
6
Charles D. Hyman
| – | -$87K | -249,625 | Closed |
|
|
WS
7
Wedbush Securities
Los Angeles,
California
| – | -$44K | -127,200 | Closed |
|
|
BIP
8
Brandes Investment Partners
La Jolla,
California
| – | -$23K | -65,000 | Closed |
|
|
9
Tudor Investment Corp
Stamford,
Connecticut
| – | -$11K | -31,660 | Closed |
|
|
BW
10
Biegel & Waller
Columbia,
Maryland
| – | -$5K | -11,500 | Closed |
|
NWBO Hedge Fund Activity: Q1 2017 in Review
4 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q1 2017, worth a combined $29K — down 100% from $8.84M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of NWBO and 2 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was Whalerock Point Partners, opening a new position worth an estimated $5K. The largest seller was Woodford Investment Management, exiting entirely with an estimated $8.64M sold.
- 4 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q1 2017, down from 8 in Q4 2016.
- Funds reported $29K of Northwest Biotherapeutics, Inc. Common stock stock for Q1 2017, down 100% quarter-over-quarter.
- 2 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q1 2017 and 6 closed out, a net change of -4 holders.
- The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q1 2017 was Whalerock Point Partners, an estimated $5K added.
- The largest Northwest Biotherapeutics, Inc. Common stock seller in Q1 2017 was Woodford Investment Management, an estimated $8.64M sold.
Based on aggregated 13F filings for Q1 2017.